Invivoscribe® is a global leader dedicated to Improving Lives with Precision Diagnostics®, advancing the quality of healthcare by providing innovative products and clinical services for oncology. Our Streamlined CDx® (companion diagnostic) model accelerates the development of novel therapeutics, enabling personalized approaches to patient care.
With products manufactured in our state-of-the-art cGMP facility, we provide a comprehensive range of platform agnostic assays, reagents, controls and software for clonal gene rearrangements, translocations, gene mutation testing, and measurable residual disease (MRD). Invivoscribe’s products consistently surpass industry and regulatory standards and play a crucial role in identifying, stratifying and monitoring hematologic cancers, enabling scientific advancements and empowering clinicians to make informed treatment decisions.
Our subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM®), offers extensive clinical diagnostic and biopharma services for the detection and monitoring of myelo- and lymphoproliferative disorders. The LabPMM network performs globally standardized flow cytometry and molecular testing services for pharmaceutical and healthcare organizations, providing results that are critically important for patient care in the U.S., Europe, and Asia.
Join us in our mission to revolutionize oncology diagnostics and improve patient outcomes worldwide. Visit our website to discover how Invivoscribe’s ecosystem is driving advancements in precision medicine.